PRACTICE GUIDELINES

Practical management of newly-diagnosed multiple myeloma: 2018 update for transplant eligible patients

BJH - volume 10, issue 3, may 2019

A. Kentos MD, C. Doyen MD, PhD, G. Bries MD, PhD, K.L. Wu MD, PhD, L. Michaux MD, PhD, M. Delforge MD, PhD, M.C. Vekemans MD, N. Meuleman MD, PhD, P. Mineur MD

With the introduction of immunomodulatory agents and proteasome inhibitors, major improvements have been achieved in the treatment and outcome of multiple myeloma. Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation remains the corner stone of therapy for fit, newly-diagnosed multiple myeloma patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.

(BELG J HEMATOL 2019;10(3):113–21)

Read more

Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases

BJH - volume 10, issue 2, march 2019

A. Janssens MD, PhD, J. Lemmens MD, S. Snauwaert MD, PhD, T. Kerre MD, PhD

High-dose chemotherapy and autologous or allogeneic haematopoietic stem cell transplantation are widely used in the treatment of lymphoproliferative diseases. For chemo-sensitive relapsed lymphoma (Hodgkin’s and non-Hodgkin’s lymphoma) high-dose chemotherapy and autologous stem cell transplantation are generally accepted as a standard treatment. Emerging data exist for the use of haematopoietic stem cell transplantation in other disease stages for mantle cell lymphoma, follicular lymphoma and some T-cell lymphomas. The use of haematopoietic stem cell transplantation in other conditions is more controversial and remains a clinical option for selected patients or experimental within the framework of a clinical trial.

(BELG J HEMATOL 2019;10(2):69–79)

Read more

Cytogenetic and molecular testing in lymphoma patients: Part 2

BJH - volume 9, issue 7, december 2018

H. Antoine-Poirel , P. Heimann MD, PhD

SUMMARY

It is now well demonstrated that cytogenetic and molecular testing are valuable tools for the diagnostic, prognostication and decision of treatment strategy in lymphoproliferative disorders. This study gives an overview of the genetic tests that represent current and future clinical assessment tools in the context of lymphoid malignancies. This review has been divided into two distinct but complementary parts. The already published part 1 addressed the genetic aspects of low grade B-cell lymphomas and very briefly described the different technical methods that can be used in routine practice for the clinical management of lymphoid malignancies. This second part covers aggressive B- and T/NK-cell lymphomas as well as Hodgkin lymphoma.

(BELG J HEMATOL 2018;9(7):266–78)

Read more

Hodgkin’s lymphoma: Belgian Hematology Society guidelines in diagnosis, treatment and follow-up

BJH - volume 9, issue 6, november 2018

A. Janssens MD, PhD, B. De Prijck MD, G. Verhoef MD, PhD, M. André MD, S. Snauwaert MD, PhD, V. De Wilde MD, PhD, V. Van Hende MD

SUMMARY

Hodgkin’s lymphoma (HL) is a rare B cell malignant neoplasm affecting approximately 300 new patients in Belgium annually. This disease represents approximately 11% of all lymphomas and comprises two discrete disease entities: classical HL and nodular lymphocyte-predominant HL. In recent years, treatment of HL patients has changed tremendously due to the use of interim PET-CT scan and the appearance of new molecules. In this article, the diagnosis, staging, treatment and long-term follow-up of patients with classical HL are discussed.

(BELG J HEMATOL 2018;9(6):214–24)

Read more

Cytogenetic and molecular testing in lymphoma patients

BJH - volume 9, issue 6, november 2018

H.A. Poirel MD, PhD, P. Heimann MD, PhD

SUMMARY

It is now well demonstrated that cytogenetic and molecular testing are valuable tools for the diagnostic, prognostication, and decision of treatment strategy in lymphoproliferative disorders. Here, we will give an overview of the genetic tests that represent current and future clinical assessment tools in the context of lymphoid malignancies. This review has been divided into two distinct but complementary parts. Part I will address the genetic aspects of low grade B-cell lymphomas and will very briefly describe the different technical methods that can be used in routine practice for the clinical management of lymphoid malignancies. Part II will cover aggressive B- and T/NK-cell lymphomas as well as Hodgkin lymphoma and will be published subsequently.

(BELG J HEMATOL 2018;9(6):225–36)

Read more

Management of cutaneous T & B cell lymphomas: a comprehensive review

BJH - volume 9, issue 3, june 2018

A. Janssens MD, PhD, C. Bonnet MD, PhD, C. Springael MD, PhD, D. Bron MD, PhD, J. Somja MD, M. de Vicq de Cumptich MD, P. Heimann MD, PhD, U. Sass MD

SUMMARY

Primary cutaneous lymphomas are a heterogeneous group of diseases with indolent or aggressive behaviour, skin-limited or systemic extension, from T or B cell origin. The optimal management requires the multi-disciplinary approach with dermatologists, hemato-oncologists, pathologists and molecular biologists. The objective of this review is to harmonise the work-up and the treatment of these different entities of cutaneous T or B cell lymphoma in Belgium, according to the availability of the drugs and specialised treatment such as extracorporeal photopherisis or total skin electron beam therapy.

(BELG J HEMATOL 2018;9(3):86–100)

Read more

Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström macroglobulinemia anno 2018

BJH - volume 9, issue 3, june 2018

A. Janssens MD, PhD, A. Van Hoof MD, PhD, D. Bron MD, PhD, V. Van Hende MD, V. Vergote MD

SUMMARY

The Belgian Haematological Society Lymphoproliferative Working Party updated the existing recommendations on best strategies for frontline and subsequent line treatment of small lymphocytic leukaemia/chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström Macroglobulinemia according to new reimbursements and robust clinical data.

(BELG J HEMATOL 2018;9(3):101–12)

Read more
X